Unknown

Dataset Information

Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia with NPM1 and FLT3-internal tandem duplication genotypes.


ABSTRACT:

Background

The revised 2017 European LeukemiaNet (ELN) classification (ELN-2017) of acute myeloid leukemia (AML) divides patients into 3 prognostic risk categories, with additional factors such as the fms-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) allele ratio (AR) considered for risk stratification. To the best of the authors' knowledge, the prognostic usefulness of ELN-2017 in comparison with ELN-2010 in younger patients with AML has not been validated to date.

Methods

The authors performed a retrospective study on patients aged <60 years who received idarubicin plus cytarabine (IA)-based induction chemotherapy for newly diagnosed AML.

Results

According to ELN-2017 criteria, the number of patients in the favorable (Fav), intermediate (Int), and

SUBMITTER: Boddu PC 

PROVIDER: S-EPMC6561101 | biostudies-literature | 2019 Apr

REPOSITORIES: biostudies-literature